We protect your health through science
Investigation
Antibiotic Resistance
Research Lines
Content with Investigacion .
Research Lines:
1. Molecular mechanisms associated to the protection of HIV-1 infection in limb-girdle muscular dystrophy dominant D2 (LGMDD2) patients.
2. Generation of neutralizing antibodies for therapeutic use based on the broad-spectrum neutralizing response against founder viruses.
3. Characterization of the immune memory against SARS-CoV-2 in a population over 65 years of age.
4. Screening and characterization of new anti-latency drugs against HIV-1.
5. Study of viral entry and HIV tropism in viruses of special epidemiological relevance in Spain.
6. Genetic mechanisms of protection and control of HIV-1 infection in populations with extreme phenotypes.
Clinical studies:
1. Phase 1 clinical trial to evaluate the safety and immunogenicity of HIV-1 envelope-based 763SIP8/MPLA-5 vaccine as a preventive vaccine in healthy uninfected adults.
2. ENE-COVID-Senior: Prospective observational study in a cohort of elderly nursing home residents to establish their immune status after receiving a complete vaccination regimen.
Implementation of new technologies:
1. Identification of HIV-1 integration sites by deep sequencing.
2. Single cell transcriptomics with simultaneous TCR/BCR sequencing.
3. Epidemiological intelligence for prediction of SARS-CoV-2 variants likely to emerge in different vaccination settings.
Research projects
Content with Investigacion .
A) Proyectos de investigación financiados en los últimos 10 años
-
Como investigadora principal
1. Impact of long-tem HCV eradication on HIV infection: integration of Immune-virologic HIV markers, host transcriptome, and plasma microbiome data. Ministerio de Ciencia (Proyectos de Generación de Conocimiento 2021). Expediente: PID2021-126781OB-I00 financiado por por MICIU/AEI /10.13039/501100011033 y por FEDER, UE Septiembre 2022 - agosto 2025. 157.300€.
2. Identificación de biomarcadores inmunológicos asociados a las infecciones virales crónicas hepatitis C y VIH relacionados con la infección por SARS-COV-2 y su pronóstico. Consejo de Educación e Investigación. Comunidad de Madrid. Doctorados Industriales. Expediente: IND2020/BMD-17373. 2021-2024. 150.000€.
3. Impacto de la erradicación y aclaramiento del VHC con los nuevos antivirales de acción directa, en pacientes coinfectados VIH/VHC en el reservorio VIH en sangre periférica y sistema inmune. Organismo Financiador: Fondo de Investigación Sanitaria (ISCIII). Expediente: PI18CIII/00020. 2019-2021. 154.000€.
4. Desarrollo de un sistema de diagnóstico in vitro para la determinación del virus de la Hepatitis C mediante nanosondas. Organismo Financiador: Comunidad Autónoma de Madrid. Doctorados Industriales. Expediente: IND2017/BMD7683. 2018-2020. 128.000€.
5. Validación preclínica de un nuevo método de diagnóstico in vitro para la determinación de la infección por el virus de la hepatitis C en humanos. Organismo financiador: BioAssays SL. Expediente: MVP-325/19. 2019-2023. 193.400€.
6. Estudio del reservorio VIH en sangre periférica y su relación con la infección por VHC, sistema inmune y perfil de microARNs. Organismo Financiador: Fondo de Investigación Sanitaria (ISCIII). Expediente: PI15CIII/00031. 2016-2018. 154.000€.
7. Development of a cell-based assay to characterize resistance mutations and drug susceptibility to protease inhibitors against hepatitis C virus and evaluation in vivo as predictors of failure. Organismo Financiador: Fondo de Investigación Sanitaria (ISCIII). Expediente: CP13/00098. 2014-2016. 120.000€.
- Como investigadora asociada
1. URBANOME (Urban Observatory for Multi-participatory Enhancement of Health and Wellbeing). IP: Saúl García Dos Santos-Alves. Agencia Financiadora: Horizon 2020 H2020-SC1-BHC-2018-2020 / H2020-SC1-2020-Two-Stage-RTDework. Call topic: Innovative actions for improving urban health and wellbeing - addressing environment, climate and socioeconomic factors". Expediente: 945391. 01/04/2021 - 01/04/2025. 268.000 €.
2. Antibiotics, hormones, persistent and mobile organic contaminants and pathogens, the complex mixture in agriculture and livestock scenario. Risk to health or natural attenuation? (Nat4Health). IP: Ana de Santiago y Raffaella Meffe. Agencia Financiadora: Ministerio de ciencia e Innovación. Convocatoria: Proyectos I+D+i 2020. Modalidad: Retos Investigación. Expediente: PID2020-118521RB-I00. 01/09/2021 - 01/09/2025. 170.000 €.
3. Inmunopatogenía del VIH. Red Temática De Investigación Cooperativa (RIS). Expediente: RD16CIII/00025. IP: Salvador Resino. (Instituto de Salud Carlos III). 01/01/2017-06/03/2022. 250.000 €.
4. Efectos de la erradicación del VHC en pacientes con cirrosis avanzada por VHC. Una aproximación traslacional. Investigador principal: Salvador Resino García. Organismo Financiador: Fondo de Investigación Sanitaria (ISCIII). Expediente: PI14/CIII/00011. 2016-2018. 154.000 €.
5. Desarrollo y mecanismo de acción de dendrímeros como microbicidas para frenar la infección por el VIH por transmisión sexual (vaginal y anal): prueba de concepto. IP: Mª Angeles Muñoz Fernández. Organismo Financiador: Fondo de Investigación Sanitaria (ISCIII). Expediente: PI13/02016. 2014-2016. 180.000 €.
6. Peptides-associated dendrimers in dendritic cells for the development of new nano-HIV vaccines. DENPEPTHIV. EuroNanoMed. IP: Mª Angeles Muñoz Fernández. Organismo financiador: Instituto de Salud Carlos III. Proyectos al amparo del Espacio Europeo de Investigación dentro del VII Programa Europeo. FP7 Cooperation Work Programme: Health-2010. Expediente: PS09102669. 2010-2013. 220.000 €.
Publications
Vaccination with LytA, LytC, or Pce of Streptococcus pneumoniae Protects against Sepsis by Inducing IgGs That Activate the Complement System
Corsini B, Aguinagalde L, Ruiz S, Domenech M, Yuste J. Vaccination with LytA, LytC, or Pce of Streptococcus pneumoniae Protects against Sepsis by Inducing IgGs That Activate the Complement System. Vaccines. 2021 Feb 23;9(2):186.
PUBMED DOIAn increase in negative supercoiling in bacteria reveals topology-reacting gene clusters and a homeostatic response mediated by the DNA topoisomerase I gene
Ferrándiz MJ, Martín-Galiano AJ, Arnanz C, Camacho-Soguero I, Tirado-Vélez JM, de la Campa AG. 2016. Nucl Acids Res. 44:7292-7303 (2016).
PUBMED DOITyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling.
Bodega-Mayor I, Delgado-Wicke P, Arrabal A, Alegría-Carrasco E, Nicolao-Gómez A, Jaén-Castaño M, Espadas C, Dopazo A, Martín-Gayo E, Gaspar ML, de Andrés B, Fernández-Ruiz E. Cell Mol Life Sci. 2024 Apr 29;81(1):199.
PUBMED DOIAdditional Information
Our general objective is to provide early knowledge about any emerging antibiotic resistance mechanism in our country. This contribution of knowledge is based on transversal objectives that we consider key, such as 1) the ability to adapt research to emerging resistance problems, 2) the promotion of cooperative and multidisciplinary research studies working in networks with different Spanish and foreign centers, 3) the transfer of research results in an agile way to the clinical practice of the national health system, and 4) the promotion of the interrelation of research with reference, advice, training and dissemination seeking the empowerment of all.
More specifically, our main scientific objectives are the characterization of the molecular bases of antibiotic resistance in pathogenic bacteria, the study of the molecular epidemiology and population structure of resistant bacteria, the characterization of the mobile genetic elements that carry resistance genes, and the development of diagnostic techniques and therapeutic alternatives against bacteria with extensive resistance to antibiotics. In this sense, research into the dissemination pathways of Enterobacteriaceae, Acinetobacter baumannii and carbapenemase-producing Pseudomonas aeruginosa (as a paradigm of extensive resistance and pan-resistance) is one of our current priority objectives.
Our general objective is to provide early knowledge about any emerging antibiotic resistance mechanism in our country. This contribution of knowledge is based on transversal objectives that we consider key, such as 1) the ability to adapt research to emerging resistance problems, 2) the promotion of cooperative and multidisciplinary research studies working in networks with different Spanish and foreign centers, 3) the transfer of research results in an agile way to the clinical practice of the national health system, and 4) the promotion of the interrelation of research with reference, advice, training and dissemination seeking the empowerment of all.
More specifically, our main scientific objectives are the characterization of the molecular bases of antibiotic resistance in pathogenic bacteria, the study of the molecular epidemiology and population structure of resistant bacteria, the characterization of the mobile genetic elements that carry resistance genes, and the development of diagnostic techniques and therapeutic alternatives against bacteria with extensive resistance to antibiotics. In this sense, research into the dissemination pathways of Enterobacteriaceae, Acinetobacter baumannii and carbapenemase-producing Pseudomonas aeruginosa (as a paradigm of extensive resistance and pan-resistance) is one of our current priority objectives.